SPL 0.00% 9.7¢ starpharma holdings limited

Ann: DEP irinotecan outperforms in pancreatic cancer model, page-22

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 12,902 Posts.
    lightbulb Created with Sketch. 1440
    The operative words say it all



    DEP® irinotecan alone showed complete tumour regression
    100% survival in a human pancreatic cancer model
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.